Literature DB >> 12469325

The proto-oncogene BCL-6 in normal and malignant B cell development.

Huifeng Niu1.   

Abstract

BCL-6 is an important regulator of the immune system. It is required for GC formation and T cell dependent antibody responses. Mice deficient in BCL-6 fail to form GC and mount reduced levels of T cell-dependent antibody responses. BCL-6 (-/-) mice, in addition, develop a massive inflammatory response in many organs characterized by eosinophilic infiltration and hyper-IgE production, a typical Th2 hyperimmune response. This suggests a negative role of BCL-6 in Th2 pathway. The BCL-6 gene encodes a POZ/zinc finger transcription repressor highly expressed in GC B cells, but not in pre-GC B cells or in more differentiated memory or plasma cells. By functioning as a potent transcriptional repressor of various target genes, BCL-6 modulates IL-4, BCR, and CD40L signals for normal B cell development. In B cell lymphomas, structural alterations of the BCL-6 promoter region, including chromosome translocation and somatic hypermutation, represent the most frequent genetic lesions associated with non-Hodgkin lymphoma, especially of diffuse large cell lymphoma, a malignancy often derived from germinal centre (GC) B cells. This suggests that deregulated expression of BCL-6 may contribute to lymphomagenesis. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12469325     DOI: 10.1002/hon.689

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  16 in total

Review 1.  Common mechanisms for the regulation of B cell differentiation and transformation by the transcriptional repressor protein BCL-6.

Authors:  Saritha Kusam; Alexander Dent
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  The dual role of sirtuins in cancer.

Authors:  Laia Bosch-Presegué; Alejandro Vaquero
Journal:  Genes Cancer       Date:  2011-06

3.  Suppression of human B cell activation by 2,3,7,8-tetrachlorodibenzo-p-dioxin involves altered regulation of B cell lymphoma-6.

Authors:  Ashwini S Phadnis-Moghe; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Sci       Date:  2014-12-26       Impact factor: 4.849

4.  New Insights Into the Persistent Effects of Acute Exposure to AFB1 on Rat Liver.

Authors:  Jiahui Yan; Lin Chen; Li Zhang; Zhaohuan Zhang; Yong Zhao; Yuan Wang; Jie Ou
Journal:  Front Microbiol       Date:  2022-06-16       Impact factor: 6.064

5.  Rac1 signaling modulates BCL-6-mediated repression of gene transcription.

Authors:  Patrícia Barros; Peter Jordan; Paulo Matos
Journal:  Mol Cell Biol       Date:  2009-06-01       Impact factor: 4.272

6.  Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy.

Authors:  Manabu Kinoshita; Naoya Hashimoto; Shuichi Izumoto; Yoshiko Okita; Naoki Kagawa; Motohiko Maruno; Takanori Ohnishi; Norio Arita; Toshiki Yoshimine
Journal:  J Neurooncol       Date:  2010-01-13       Impact factor: 4.130

7.  EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts.

Authors:  Jing Fang; Madhu Menon; William Kapelle; Olga Bogacheva; Oleg Bogachev; Estelle Houde; Sarah Browne; Pradeep Sathyanarayana; Don M Wojchowski
Journal:  Blood       Date:  2007-06-04       Impact factor: 22.113

8.  TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice.

Authors:  Juan M Zapata; Maryla Krajewska; Herbert C Morse; Yongwon Choi; John C Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-15       Impact factor: 11.205

9.  Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters.

Authors:  Patrícia Barros; Eric W-F Lam; Peter Jordan; Paulo Matos
Journal:  Nucleic Acids Res       Date:  2012-06-20       Impact factor: 16.971

10.  Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer.

Authors:  K Kim; G Chadalapaka; S-O Lee; D Yamada; X Sastre-Garau; P-A Defossez; Y-Y Park; J-S Lee; S Safe
Journal:  Oncogene       Date:  2011-07-18       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.